Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 6/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20384187 | 0.98 | CSNK2A1 (0.43) | CSNK2A1PDE4ANPY1RNPY2RMCHR1 | |
| SCHEMBL21191007 | 0.85 | SYK (0.44) | CSNK2A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20443368 | 0.85 | MCHR1 (0.43) | CSNK2A1PDE4ANPY1RNPY2RMCHR1 | |
| SCHEMBL20384398 | 0.82 | BRD4 (0.33) | CSNK2A1PDE4A | |
| SCHEMBL4478298 | 0.82 | HRH3 (0.44) | KMT2AMEN1 | |
| SCHEMBL10012300 | 0.80 | CSNK2A1 (0.45) | CSNK2A1PDE4AMCHR1PDE4BPDE4C | |
| SCHEMBL28730569 | 0.80 | PDE4B (0.36) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL28730568 | 0.80 | PDE4B (0.36) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL16335376 | 0.79 | PKM (0.42) | CSNK2A1PDE4ANPY1RNPY2RPOLB | |
| SCHEMBL3723725 | 0.79 | CSNK2A1 (0.41) | CSNK2A1PDE4ANPY1RNPY2RPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | CSNK2A1 1014/4885PDE4A 4232/4885NPY1R 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.